

DEC 02 2002

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/085,418
Filing Date	02/28/2002
First Named Inventor	Alexandra Louise Lowe
Group Art Unit	1636
Examiner Name	
Attorney Docket Number	50223/USTN2/UST

Total Number of Pages in This Submission: 14

**ENCLOSURES (check all that apply)**

- ☐ Fee Transmittal Form
- ☐ Fee Attached
- ☐ Amendment / Reply
- ☐ After Final
- ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☐ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☒ Response to Missing Parts/  
Incomplete Application
- ☐ Response to Missing Parts  
under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers  
(for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a  
Provisional Application
- ☐ Power of Attorney, Revocation  
Change of Correspondence  
Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) \_\_\_\_\_

- ☐ After Allowance Communication  
to Group
- ☐ Appeal Communication to Board  
of Appeals and Interferences
- ☐ Appeal Communication to Group  
(Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) (please  
identify below):  
Diskette  
Paper Copy of Seq. Listing  
Notice to Comply  
Postcard  
Verification Statement

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name	Mary Kakefuda
Signature	<i>Mary Kakefuda</i>
Date	11/19/2002

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

11-19-2002

Signature \_\_\_\_\_ Date \_\_\_\_\_

Estimated Time Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



CASE 50223/USTN2/UST

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, Washington, D.C. 20231.

Laneisha C. Hayes  
Type or print name

*Laneisha C. Hayes*  
Signature

November 19, 2002  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF

LOWE ET AL.

APPLICATION NO: 10/085,418

FILED: February 28, 2002

FOR: GENE SILENCING

**Attention: Box Missing Parts**

Commissioner for Patents  
Washington, DC 20231

**RESPONSE TO NOTICE TO COMPLY**

Sir:


The Notice to Comply dated November 7, 2002 (a copy of which is enclosed) has a shortened statutory time set to expire on January 7, 2002. The Notice states missing items were (1) a corrected sequence listing in paper and computer readable form; (2) a Statement under CFR § 1.821 et seq and (3) Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures.

Enclosed are copies of a Corrected nucleotide and/or amino acid sequence submission, including a computer readable copy, a paper copy and a Statement Verifying Identity of Above Copies.

The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, to Account No. 50-1744 in the name of Syngenta.

Respectfully submitted,

Syngenta Biotechnology, Inc.  
Patent Department  
P.O. Box 12257  
Research Triangle Park, NC 27709-2257  
(919) 597-5071  
Date: November 19, 2002

  
\_\_\_\_\_  
Mary Kakefuda  
Attorney for Applicants  
Reg. No. 39,245

341 97 7037

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h1 style="text-align: center;">TRANSMITTAL FORM</h1> <p style="text-align: center;">(to be used for all correspondence after initial filing)</p>	Application Number	10/085,418	
	Filing Date	02/28/2002	
	First Named Inventor	Alexandra Louise Lowe	
	Group Art Unit	1636	
	Examiner Name		
Total Number of Pages in This Submission	4	Attorney Docket Number	50223

TECH CENTER 1600/2900

DEC 05 2002

RECEIVED


ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Associate Power of Attorney Change of Address
Remarks: _____		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mary Kakefuda
Signature	<i>Mary Kakefuda</i>
Date	1/17/02

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: <span style="border: 1px solid black; padding: 2px;">11-19-2002</span>	

Signature	Date
-----------	------

Burden Hour Statement: This form is estimated to take 1-2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Attorney Docket No.: 50223/USTN2/UST

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

LOWE ET AL.

APPLICATION NO: 10/085,418

FILED: February 28, 2002

FOR: Gene Silencing

BOX: Missing Parts  
Commissioner for Patents  
Washington, D.C. 20231


SUBMISSION OF SEQUENCE LISTING  
INCLUDING STATEMENT OF VERIFICATION

Sir:

Applicants hereby provide a Computer Readable Form of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Syngenta Biotechnology, Inc.  
Patent Department  
P.O. Box 12257  
Research Triangle Park, NC 27709-2257

  
\_\_\_\_\_  
Mary Kakeluda  
Attorney for Applicants  
Reg. No. 39,245  
Phone: (919) 765-5071

Date: November 19, 2002



UNITED STATES  
PATENT AND  
TRADEMARK OFFICE

DEC 02 2002

PATENT & TRADEMARK OFFICE

HALE AND DORR LLP

HALE & DORR LLP CCKETING

RE: 109846306 US2

Action Date: Trans

Action to be Taken: none

Docketed By: C 02-11-14-02

Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/085,418	02/28/2002	Alexandra Louise Lowe	109846.152 (SYN-047 CN2)

23483  
HALE AND DORR, LLP  
60 STATE STREET  
BOSTON, MA 02109

DOCKET  
DEPT.  
INTELLECTUAL PROPERTY  
DEPARTMENT

CONFIRMATION NO. 4860

FORMALITIES LETTER



\*OC000000009081823\*

Date Mailed: 11/07/2002

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

2/1/02

PARTIAL ATTORNEY/APPLICANT COPY



HALE and DORR, LLP  
1455 Pennsylvania Avenue, NW  
Washington, DC 20004  
(202) 942-8400

Applicant(s):	LOWE et al.	Serial No.:	10/085,418
Filing Date:	28 February 2002	Atty. Docket No.:	109846.306 (SYN-047CN2)
Entitled:	GENE SILENCING		

RECEIPT IS ACKNOWLEDGED FOR THE FOLLOWING:

- ☒ [X] Transmittal Letter;
- ☒ [X] Part 2 – Return Copy of Notice to File Corrected Application papers and Raw Sequence Listing Error Report;
- ☒ [X] Response to Notice to File Corrected Application Papers and Second Preliminary Amendment with Appendix A (Amendment to Specification – Clean Version); and Appendix B (Amendment to Specification – Marked-up Version);
- ☒ [X] Sequence Listing on Computer Readable Format;
- ☒ [X] Copy of Sequence Listing on Paper;
- ☒ [X] Statement Under 37 C.F.R. § 1.821(f); and
- ☒ [X] postcard evidencing the same.

ATTY/TMP:msb

